Welcome to our dedicated page for Cue Biopharma news (Ticker: CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.
Cue Biopharma Inc (NASDAQ: CUE) is a clinical-stage biopharmaceutical company pioneering targeted immunotherapies through its innovative Immuno-STAT platform. This page serves as the definitive source for official company announcements, research developments, and strategic updates.
Investors and industry observers will find curated press releases covering clinical trial progress, regulatory milestones, and partnership announcements. Our collection includes updates on CUE-100 series candidates for oncology applications and autoimmune disease programs, along with financial reporting and executive commentary.
All content is sourced directly from company filings and authorized communications, ensuring reliability for those monitoring advancements in T cell-modulating therapies. Key focus areas include phase 1/2 trial results, platform technology enhancements, and collaboration updates with leading research institutions.
Bookmark this page for streamlined access to Cue Biopharma's latest scientific achievements and corporate developments in the competitive immunotherapy landscape. Check regularly for real-time updates on this innovative biologics developer.
Cue Biopharma, a clinical-stage biopharmaceutical company, will host a conference call and webcast on August 17, 2021, at 4:30 p.m. EDT to share a business update. The session will provide updates on its lead drug candidate CUE-101, currently in Phase 1b trials for treating HPV+ head and neck cancer. The management team will discuss updates from ongoing clinical trials, including combination trials with Merck’s KEYTRUDA, and advancements in their Immuno-STAT™ technology platform. Details for accessing the call and webcast are available on their website.
On August 3, 2021, Cue Biopharma (Nasdaq: CUE) announced participation in the BTIG Virtual Biotechnology Conference scheduled for August 9-10, 2021. During the fireside chat on August 10, at 3:00 p.m. EDT, the company will share updates on its clinical programs, particularly the CUE-101 therapeutic for HPV+ recurrent head and neck cancer. The discussion will also cover advancements in their pipeline, including the upcoming Phase 1 trial for CUE-102 targeting the Wilms' tumor 1 (WT1) antigen expected to start in early 2022.
On June 14, 2021, Cue Biopharma (CUE) announced participation in the JMP Securities Life Sciences Conference on June 16-17, 2021. The company will discuss the Phase 1a/1b clinical trial of CUE-101 for treating HPV+ recurrent/metastatic head and neck cancer. Notable updates include the initiation of patient expansion in Part B at a recommended dose of 4 mg/kg, enrolling up to 20 patients. Encouraging trial results show six stable disease cases and one partial response. Cue Biopharma will also highlight additional projects, including CUE-102 and CUE-401.
On June 10, 2021, Cue Biopharma (CUE) announced it has dosed the first patient in the Part B expansion phase of its Phase 1 monotherapy clinical trial for CUE-101, targeting HPV+ head and neck squamous cell carcinoma. This trial will expand to enroll up to 20 patients, following promising results from Phase 1a, where six patients had stable disease and one demonstrated a 50% tumor reduction. The company aims for CUE-101 to potentially enter registration-directed trials based on these encouraging findings, highlighting its innovative approach to cancer treatment.
Cue Biopharma (Nasdaq: CUE) announced plans to present at the 2021 Federation of Clinical Immunology Societies Annual Meeting from June 8-11, 2021. Anish Suri, the company's president, will discuss preclinical data on CUE-401, aimed at treating autoimmune diseases. CUE-401 is a bispecific molecule designed to induce regulatory T cells (iTregs) in vivo. The presentation is scheduled for June 10, 2021, and will highlight its effectiveness in inducing iTregs from healthy donors and patients with autoimmune conditions like rheumatoid arthritis.
Cue Biopharma (CUE) has announced its participation in the Jefferies Virtual Healthcare Conference from June 1-4, 2021. The company will showcase its advancements, particularly focusing on CUE-101, an Immuno-STAT™ therapeutic being tested for HPV+ recurrent/metastatic head and neck cancer. Additionally, Cue Biopharma will discuss CUE-102, a drug candidate targeting Wilms Tumor 1 (WT1), with an IND filing expected in the first half of 2022. The presentation is scheduled for June 3, 2021, at 8:30 a.m. EDT, and will be available for live streaming.
On May 17, 2021, Cue Biopharma provided a clinical and business update for Q1 2021. The company reported a confirmed partial response in a patient from its Phase 1 monotherapy trial of CUE-101, with stable disease observed in five patients. Cue Biopharma's collaboration revenue increased to approximately $1.6 million, while R&D expenses slightly decreased to $9.8 million. The firm strengthened its financial position by raising $10.4 million through its ATM facility. The company ends Q1 2021 with cash and equivalents of $73.3 million, supporting operations through Q4 2022.
Cue Biopharma (CUE) has announced a conference call and webcast scheduled for May 17, 2021, at 4:30 p.m. EDT to share a business update. This includes a clinical update on the ongoing Phase 1a/1b trial of CUE-101, with emphasis on a confirmed partial response in a patient treated for HPV+ recurrent/metastatic head and neck squamous cell carcinoma. The management will also discuss recent advancements in their technology platform and strategic objectives. Investors can access the event via the company's website.
Cue Biopharma (CUE) announced interim clinical data from its Phase 1a/1b study of CUE-101, showing a confirmed partial response (PR) in a patient with HPV+ recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). This marks initial clinical proof of concept for its Immuno-STAT™ platform, highlighting activity in modulating the anti-tumor T-cell repertoire. The study reported favorable tolerability and evidence of immune cell activation. The company plans to discuss these findings in its upcoming quarterly update on May 17, 2021.
On May 6, 2021, Cue Biopharma (Nasdaq: CUE) announced it will present at the virtual New York Academy of Sciences 2021 Frontiers in Cancer Immunotherapy meeting from May 12-14, 2021. The presentation will focus on the Immuno-STAT™ platform, designed to enhance anti-tumor immune responses, alongside its expanding pipeline including lead candidate CUE-101, which targets HPV+ head and neck squamous cell carcinoma. Dr. Steve Quayle will discuss clinical data demonstrating favorable activity for CUE-101 and introduce CUE-102, targeting WT1, expected to enter clinical trials in 2022.
FAQ
What is the current stock price of Cue Biopharma (CUE)?
What is the market cap of Cue Biopharma (CUE)?
